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CytogeneticsMarek’s disease (MD) is a lymphotropic and oncogenic disease of chickens that can lead to death in sus-
ceptible and unvaccinated host birds. The causative pathogen, MD virus (MDV), a highly oncogenic alpha-
herpesvirus, integrates into host genome near the telomeres. MD occurrence is controlled across the
globe by biosecurity, selective breeding for enhanced MD genetic resistance, and widespread vaccination
of flocks using attenuated serotype 1 MDV or other serotypes. Despite over 40 years of usage, the specific
mechanism(s) of MD vaccine-related immunity and anti-tumor effects are not known. Here we investi-
gated the cytogenetic interactions of commonly used MD vaccine strains of all three serotypes (HVT,
SB-1, and Rispens) with the host to determine if all were equally capable of host genome integration.
We also studied the dynamic profiles of chromosomal association and integration of the three vaccine
strains, a first for MD vaccine research. Our cytogenetic data provide evidence that all three MD vaccine
strains tested integrate in the chicken host genome as early as 1 day after vaccination similar to onco-
genic strains. However, a specific, transformation-associated virus-host phenotype observed for onco-
genic viruses is not established. Our results collectively provide an updated model of MD vaccine-host
genome interaction and an improved understanding of the possible mechanisms of vaccinal immunity.
Physical integration of the oncogenic MDV genome into host chromosomes along with cessation of viral
replication appears to have joint signification in MDV’s ability to induce oncogenic transformation.
Whereas for MD vaccine serotypes, a sustained viral replication stage and lack of the chromosome-
integrated only stage were shared traits during early infection.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Marek’s disease (MD) is a lymphotropic disease of chickens
characterized by fatal lymphoma development in the visceral
organs, paralysis and blindness in susceptible birds. The causative
alphaherpesvirus [1,2], Marek’s disease virus (MDV aka gallidherpesvirus type 2 or serotype 1), is known to integrate into
chicken telomeres [3–5]. The MDV genome contains homologous
host genes and telomeric repeats, which were presumably
acquired through recombination and/or integration and reemer-
gence events during the course of the virus’ evolutionary history
[6–8]. As a herpesvirus, the life cycle of virulent strains involves
transitioning from a stage of cytolytic replication in the episomal
form to a latent stage, by which MDV evades host immune
responses [9–14]. Furthermore, latent host CD4+ T lymphocytes
become transformed after serotype-1 oncogenic MDV infection,
between 14 and 21 days post-infection (dpi), resulting in lym-
phomas [15–19]. Telomeric integration of MDV is temporally
related to latency [4,5]. Furthermore, latently-infected MD cell
lines consist of primarily host genome integrated MDV, rather than
extra-chromosomal viral DNA [3,20]. MDV telomeric repeats facil-
itate integration into chicken telomeres [21,22], although the pre-
cise mechanism of integration is not fully known. The viral Meq
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ical roles in host cell transformation [23–25]. Interestingly, a Meq-
deleted (DMeq) MDV strain that does not induce MD lymphomas
in vivo [26] can integrate into the chicken genome, but lacks a
transformation-coupled viral-host phenotype in lymphocytes [5].
Osterrieder and colleagues presented experimental data suggest-
ing that vTR is involved in telomeric integration of MDV [9].
MD can be controlled by selective breeding for increase genetic
resistance, however, in commercial production systems, the pri-
mary control method is widespread vaccination [16]. An effective
MD vaccine, the related herpesvirus of turkey (HVT; meleagrid her-
pesvirus type 1 aka serotype 3) [27,28], was first employed in the
early 1970s. Field strain virulency increased (very virulent (vv) to
vv+ ratings) through the late 1970s resulting in more outbreaks
until bivalent vaccine [SB-1 (gallid herpesvirus type 3 or serotype
2) + HVT] and, later, the attenuated serotype 1 Rispens/CV1988
vaccine were employed [29,30]. The Rispens vaccine provides the
highest level of protection against vv+ MDV, although its protective
efficiency varies with bird major histocompatibility complex
(MHC) haplotype [31]. These non-oncogenic, vaccine strains have
been detected in a latent form in vivo, but do not induce MD lym-
phomas [32]. Current vaccination strategies do not elicit sterilizing
immunity [18]. The specific mechanisms of vaccine-related immu-
nity are not known, although reduced growth rate of MDV [33],
increased late reactivity of peripheral blood lymphocytes to mito-
gens (in the case of HVT) [34] and prevention of immunosuppres-
sive effect in the host [35] may contribute in addition to vaccine
strain(s) interference with the infection process of oncogenic
MDV in T and B lymphocytes [36,37]. However, supplementary
mechanisms are certainly involved [9,15] and an explanation for
the anti-tumor effect of vaccination has not yet been established.
Furthermore, the underlying features of the vaccinal protective
mechanism undoubtedly vary among the vaccine serotypes.
Although the genomes of oncogenic and vaccine strains are
highly similar, key differences exist [38] (see Table 1 p.2). A shared
aspect among serotypes is the presence of telomeric repeats
between the inverted repeats long (IRL)/short (IRS) and terminal
repeats long (TRL)/short (TRS) of the viruses. The presence of telom-
eric repeats in both oncogenic and vaccine MDV strains suggests
that the vaccines could be capable of integrating into telomeres
of host lymphocytes, despite differences in or the absence of, mul-
tiple disease-associated genes (Meq, vTR, vIL8, etc.) [39]. Our cen-
tral hypothesis is that MD vaccines integrate into the chicken
genome at the telomeres. This vaccinal interaction with the host
genome, in addition to various other behaviors that contribute to
the vaccinal protective mechanism, may disrupt aspects of infec-
tion, latency, and/or the transformation cycle of the oncogenic
MDV strain(s). Here we sought to test our hypothesis by investigat-
ing interactions of MD vaccines with the host at the level of the
genome (i.e., study virus chromosomal association and integration
profiles) via cytogenetic methods.2. Materials and methods
2.1. Genetic lines and vaccination/challenge
Experimental birds were progeny of a cross between two highly
inbred, MD susceptible lines 72 and 15I5 from the USDA, ARS, Avian
Disease and Oncology Laboratory (ADOL), cared for under
approved animal care protocols by trained staff. All institutional
(ADOL Institutional Animal Care and Use Committee) and national
(USA National Research Council of the National Academies) guide-
lines for the appropriate care and use of laboratory animals were
closely followed throughout the experiments. One week post-
hatch, F1 chicks were intra-abdominally vaccinated with 5000pfu of HVT, SB-1, or Rispens alone, or challenged with GA onco-
genic MDV alone or received no treatment. Chicks were hatched
and maintained in Horsfall-Bauer isolation chambers at the USDA
facility.
2.2. Spleen sample collection and processing
Mitotic chromosome preparations were harvested from spleen
samples collected at 1, 4, 7, 14 and 21 days post-infection (dpi).
Spleen cell suspensions were treated with 100 ll of colcemid
(10 lg/ml, Invitrogen, Waltham, MA, USA) in cell culture medium
for 30–60 min. Single cell suspensions were generated from each
spleen and exposed to 0.56% KCl hypotonic solution (30 min) and
then fixed in 3:1 methanol and glacial acetic acid (several fixes
over one to three days) according to standard procedures. The
chromosome spreads were applied to slides using the air-dry
method after the third fixative change, as described by Delany
et al. [40]. All chromosome slides were stored according to Delany
et al. [40] until further use in FISH experiments, where they were
left at room temperature in a slide box for at least 24 h to allow
thawing and for condensation to be absorbed by fresh desiccant.
2.3. MDV-specific probes and probe labeling
The DNA probe utilized for hybridization to MDV genome was
an Md11 bacterial artificial chromosome (BAC) (Md11gDc1.2 [7]).
The probes were labeled using nick translation with Digoxigenin
(DIG) dUTP through a DIG Nick Translation kit (Roche Applied
Science, Indianapolis, IN, USA). An anti-digoxigenin secondary anti-
body (Roche Applied Science) conjugated with Fluorescein isothio-
cyanate (FITC, green) was then applied. Due to the presence of
chicken telomeric repeats (TTAGGGn) in the Md11 BAC probe,
telomeric DNA sequence in the chicken genome was blocked with
approximately 280 ng/uL of custom telomere oligonucleotide
(TTAGGG7), also called ‘‘cold telo.”
2.4. Fluorescence in situ hybridization (FISH)
Slide hybridization was completed by standard FISH procedures
as described by Delany et al. [40] with adaptations for labeling
MDV; (1) the Md11 BAC probe was applied; (2) cold telo was
utilized to block host telomeric DNA. The preparations were coun-
terstained with Vectashield Mounting Medium (Vector Laborato-
ries, Burlingame, CA, USA) and 40,6-diamidino-2-phenylindole
(DAPI, Vector Laboratories) diluted 1:9 (DAPI:VS). Prior to analysis,
the slides were stored flat at 4 C and image capture occurred
within 24 h of FISH and DAPI counterstaining.
2.5. Cytogenetic analysis
Metaphase and interphase cell images were collected using an
Olympus BX41 epifluorescence microscope equipped with an auto-
matic filter wheel (Chroma Technology 82000, DAPI/fluorescein
isothiocyanate/tetra methyl rhodamine isothiocyanate filter set),
X-Cite 120 Series metal-halide fiber optic lamp, and Applied Imag-
ing software (CytoVision 7.4 GENUS, Leica Biosystems, Buffalo
Grove, IL, USA). Between 10 and 80 spleen cell images were ana-
lyzed per sample (representing an individual spleen from a bird)
in each FISH experiment. Negative control (no treatment) samples
were incorporated in most MDV FISH experiments to ensure that
the Md11 BAC probe was hybridizing specifically to the MDV gen-
ome, as indicated by the absence of FITC signals from all terminal
and interstitial telomeres, as described by Robinson et al. [4]. All
captured mitotic metaphase cells were categorized as one of four
cytogenetic viral phenotypes as previously described [4,38] and
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(dispersed signals over and around the chromosomes);
chromosome-associated and telomere-integrated (associated
signals along with distinct, punctate and bright signal(s)); or
telomere-integrated only (only the distinct telomeric signals
detected).Fig. 1. Temporal dynamics of MDV vaccine-host genome interactions in spleen mitotic
images of the cytogenetic phenotypes observed, which signify the status of the herpesviru
of the corresponding data for those phenotypes. The null phenotype lacks viral FISH si
associated phenotype is defined by diffuse viral FISH signals surrounding the host chrom
of both the diffuse associated signals and bright, punctate integrated-virus signals at the
distinct, punctate FISH signals at the telomeres. For the corresponding phenotype-data
given phenotype ± SEM for 3 birds per treatment group across all early timepoints (1–21
MD vaccine (Rispens; blue, SB-1; purple, HVT; green), respectively. (For interpretation of
of this article.)2.6. Statistical analysis
The mean values of metaphase cells with the specific pheno-
types were evaluated by the multiple comparison of means test
in R (R Core Team, version 3.2.1, 2015) [41] across timepoints and
treatment groups to establish statistically significant differences.cell populations: patterns of virus-host phenotypes over time. Representative FISH
s with regard to the chicken host genome in mitotic cells of the spleen, are to the left
gnals (FITC, green) around the chromosomes (DAPI, blue). The viral chromosome-
osomes while the chromosome-associated/telomere-integrated phenotype consists
telomeres. The telomere-integrated only viral phenotype is exclusively comprised of
graphs, the lines represent the mean percentage of mitotically dividing cells with a
dpi). The oncogenic MDV (GA; red) phenotype data is compared to the data for each
the references to color in this figure legend, the reader is referred to the web version
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formed using a logit transformation (logit (k/n) = ln {k + 1/n  k
+ 1}), in which k out of n cells were observed for any given viral
phenotype within a bird and timepoint. The logit or logarithm of
the odds transformation is applied to fit categorical data in the
form of proportions to a linear model. The normalized data were
then analyzed by two-factor ANOVA and, subsequently, Tukey’s
multiple comparisons of means with a 95% family-wise confidence
interval. The Tukey’s method of multiple comparison analysis tests
all pairwise differences between groups, even when unequal group
sizes exist, and reduces the probability of type I error through use
of the q statistic. The effects of MDV strain and days post infec-
tion/vaccination on phenotype were calculated. The count of meta-
phase cells identified within each phenotype was the dependent
variable in ANOVA analysis.
3. Results
We investigated virus-host chromosomal association and inte-
gration profiles of three MDV serotypes (three vaccines, one onco-
genic strain) in three animals per treatment group at each of five
timepoints. As is commonly observed with MD research results,
inter-individual variation within a treatment group was evident
for virus-host phenotypes despite identical host genetic back-
grounds, tissue sampled, bird ages, timing of vaccination/challenge
and sample conditions, including vaccine/challenge dosages and
environmental conditions.
3.1. MD vaccines integrate in the chicken host genome
Our results showed evidence of viral integration, i.e., punctate
viral (FITC, green) signals at the telomeres of mitotic metaphase
chromosomes of spleen cells, in the MDV challenged (GA) birds,
and also in all MD vaccinated (Rispens, SB-1, HVT) birds. The
appearance (distinct, bright, and frequently doublet sister chro-
matid signals) and location of these FITC signals indicate that theyTable 1
A comparison of viral-host cytogenetic interactions for oncogenic and vaccine MDV strain
Days post infection Virus type Phenotype
Null Chromosome-a
1 GA 13.7 ± 6.7 41.8 ± 2.7
1 Rispens 27.5 ± 5 38.8 ± 13.6
1 SB-1 41.4 ± 28.6 48.1 ± 27.9
1 HVT 35.4 ± 3 41.1 ± 17.2
4 GA 16.5 ± 14.3 25.6 ± 20
4 Rispens 27.6 ± 3.6 46.4 ± 9.5
4 SB-1 43.1 ± 12.9 37.7 ± 15
4 HVT 30.3 ± 17.5 29 ± 7.8
7 GA 21.5 ± 3.6 11.9 ± 5.8
7 Rispens 57.3 ± 18.4 22.8 ± 7.1
7 SB-1 27.8 ± 15.1 50.8 ± 7.2
7 HVT 36.7 ± 15.3 39.5 ± 18.4
14 GA 23.8 ± 2.7 20.1 ± 3.9
14 Rispens 49.3 ± 15.3 30.8 ± 6.1
14 SB-1 19.9 ± 14.7 73.7⁄b ± 18.8
14 HVT 65.6 ± 14.4 31.3 ± 12
21 GA 30.7 ± 16.4 12 ± 20.7
21 Rispens 38.6 ± 4.5 40.9 ± 17.1
21 SB-1 17.8 ± 13.9 45.6 ± 17.1
21 HVT 24.7 ± 3.5 32.5 ± 6.6
The mean percentages ± standard deviation of 3 birds with given virus-host cytogenetic
vaccine strains: Rispens, SB-1, HVT) over five timepoints (1–21 dpi). See Methods and
statistically significant within a viral phenotype for a treatment group (MDV strain) ove
statistically significantly different as compared to the other treatment groups (MDV strai
‘‘⁄b” symbol (p < 0.05).represent telomere-integrated MDV genome as a long concatemer.
For all treatment groups (excluding the negative control),
telomere-integrated MDV signals were detected in spleen cells
immediately post-treatment (1 dpi) through to 21 dpi (Fig. 1).
Although all MDV challenged or vaccinated birds presented with
telomere-integrated virus, the frequency of MDV integration dis-
played a notable degree of inter-individual variation within and,
more significantly, between treatment groups, consistent with
prior research [4,5]. Across all timepoints, oncogenic MDV (GA)
integrated into the host telomeres in a higher percentage of cells
as compared the MD vaccines. Furthermore, the GA-challenged
birds exhibited both the MDV chromosome-associated/telomere-i
ntegrated phenotype and the telomere-integrated only phenotype.
However, the MD vaccinated-birds lacked the telomere-integrated
only phenotype between 1 and 21 dpi in the spleen (Table 1),
except in rare instances (single cell from a Rispens-vaccinated
sample at 7 dpi, and from HVT-vaccinated samples at 1 and 4 dpi).
3.2. Cytogenetic interactions with the host genome
3.2.1. Rispens vaccine versus oncogenic MDV
The Rispens vaccination treatment group had a higher mean
percentage of cells with the MDV-null and MDV-chromosome-
associated phenotypes across all time points, with the exception
of 1 dpi for the latter phenotype, as compared to the GA-
challenged group (Fig. 1). The Rispens-vaccinated birds also
demonstrated a lower mean percentage of cells with the MDV-chro
mosome-associated/telomere-integrated phenotype at all time-
points. These results could reflect a longer cytolytic stage for the
non-oncogenic Rispens virus as compared to oncogenic/virulent
MDV, perhaps due to inability of the vaccine-virus to efficiently
or entirely transition into latency in host cells. Most changes in
the percentage of cells with the MDV-chromosome-associated
phenotype, likely representative of viral lytic replication, were
reflected by inverse changes in the percentage of cells with the
MDV-null phenotype at the same time points (while the transi-s in the splenic cell populations during early infection.
ssociated Chromosome-associated/
telomere-integrated
Telomere-integrated only
44.5 ± 8.1 0 ± 0
33.7 ± 18 0 ± 0
10.5 ± 7.8 0 ± 0
22.1 ± 14.2 0.7 ± 1.2
57.9 ± 33.3 0 ± 0
25.9 ± 10.5 0 ± 0
19.2 ± 16.2 0 ± 0
40.1 ± 19.4 0.5 ± 0.9
53.6⁄b ± 9.5 13.1⁄b ± 5.3
18.7 ± 11.4 1.3 ± 1.1
21.5 ± 8.2 0 ± 0
23.1 ± 8.7 0 ± 0
41.5 ± 8.2 14.7 ± 11.2
19.9 ± 11.6 0 ± 0
6.4 ± 6 0 ± 0
3.1⁄a ± 3.7 0 ± 0
34.8 ± 5.1 22.7⁄b ± 11.3
20.6 ± 14.7 0 ± 0
36.7 ± 26.5 0 ± 0
42.8 ± 9.8 0 ± 0
phenotypes for each of the treatment groups (oncogenic strain: GA, non-oncogenic
Results for virus-host phenotype explanations. The values that were found to be
r time are indicated in bold font and a ‘‘⁄a” symbol (p < 0.05). The values that were
ns) within a timepoint and within a viral phenotype are indicated in italic font and a
5558 M.C. McPherson et al. / Vaccine 34 (2016) 5554–5561tional viral phenotype showed no detectable shifts). This can be
most prominently observed at 7 dpi, whereupon the mean
percentage of cells with the null phenotype increases as the per-
centage of MDV-chromosome-associated phenotype declines com-
pared to 4 dpi (Fig. 1). Thus, reduction in replicating Rispens virus
in the spleen may be due to viral clearing by the host immune
responses, rather than explained by the Rispens vaccine-virus tran-
sitioning into latency during early infection (1–21 dpi). Conversely,
GA MDV shows an increasing population of cells with the
telomere-integrated only phenotype as the percentages of cells
with the chromosomes-associated phenotypes decline between 4
and 21 dpi.
3.2.2. SB-1 vaccine versus oncogenic MDV
SB-1 vaccine treatment showed a unique trend for the MDV null
phenotype as compared to the other vaccine types (Rispens or
HVT). The mean percentage of cells with this phenotype for the
vaccinated birds was initially higher than that of the challenged
birds as was the circumstance for the other two vaccinated groups.
However, the null phenotype declines steadily from 4 to 21 dpi and
drops below the mean percentage observed for the GA-challenged
birds by 14 dpi. The distinctly low percentage of MDV-null cells at
the later timepoints (14 and 21 dpi) may indicate that the SB-1
vaccine-virus is able to establish a particularly prolonged cytolytic
replication stage in the host and/or better evade host immune
responses during early infection.
Similar to the other vaccination groups, the SB-1 vaccinated
birds consistently demonstrated a higher mean percentage of cells
with the MDV chromosome-associated phenotype, which appears
to represent a cytolytic stage of infection, as compared to the
GA-challenged birds through all timepoints of early vaccination/
infection (1–21 dpi). There was also a notable increase in cells with
this viral phenotype at 14 dpi, which was significantly different
(p < 0.05) from the mean percentages across timepoints and within
the phenotype for SB-1 vaccinated birds. The significant increase in
the percentage of cells with the MDV chromosome-associated phe-
notype observed at 14 dpi was mirrored by a decrease in the MDV
chromosome-associated and telomere-integrated phenotype,
while the MDV null phenotype continued on a steady downward
trend.
3.2.3. HVT vaccine versus oncogenic MDV
The HVT-vaccinated treatment group demonstrated a higher
percentage of cells in the spleen with the MDV chromosome-
associated phenotype, representing cytolytic replication in host
nuclei, as compared to the oncogenic MDV-challenged group at
all timepoint except 1 dpi. This may represent a higher and more
sustained lytic infection by the HVT vaccine-virus as compared to
oncogenic MDV. The percentage of cells with the null phenotype
(no virus detected) was also higher in the vaccinated birds until
21 dpi. Conversely, the percentage of dividing cells with the MDV
chromosome-associated and telomere-integrated phenotype was
lower for the HVT treatment group as compared to the challenged
group until 21 dpi.
At 14 dpi, a significant (p < 0.05) decrease in the mean percent-
age of mitotic cells with the transitional (MDV chromosome-
associated and telomere-integrated) phenotype was observed in
HVT-vaccinated birds. The dramatic reduction in this viral pheno-
type was accompanied by a notable increase in the MDV null phe-
notype (no MDV detected). The large shift in MD vaccine presence
within the spleen may be explained by a decline in MDV-infected
cells following host adaptive immune response and infected host
cell targeting. It is interesting that there is no significant change
in the MDV chromosome-associated only phenotype at 14 dpi.
The subsequent increase in the transitional phenotype at 21 dpi
may indicate viral infection ‘‘rebound” in the spleen, perhaps dueto a failure of the immune response to completely clear the virus.
Interestingly, the mean percentage of mitotically dividing cells
with the transitional phenotype in HVT-vaccinated birds surpasses
that of the GA-challenged birds, while the percentage of cells with
the MDV null phenotype in the vaccinated group falls below that of
the challenged group, at 21 dpi.4. Discussion
Prior research has shown [4,5] that the MDV telomere-
integrated only phenotype is strongly associated with the timing
of viral latency and host cell transformation in birds infected with
oncogenic MDV strains. Furthermore, >90% of mitotically dividing
cells in MDV-induced lymphomas exhibit the MDV telomere-
integrated only phenotype [5]. The MDV chromosome-associ
ated/telomere-integrated phenotype may represent a transitional
phase of the viral life cycle from lytic replication to latency (for
most MDV strains) and transformation (in the case of oncogenic
MDV). However, it is not yet known if this transitional virus-host
phenotype presented with the MDV chromosome-associated phe-
notype at an earlier timepoint or established the transitional phe-
notype upon initial MDV infection. Rarely, T lymphocytes infected
with latent MDV will undergo oncogenic transformation and,
among those cells, a few will establish as tumors (i.e., T cell lym-
phomas in the visceral organs). The telomere integrated-only
MDV phenotype likely represents a ‘‘transformation susceptible”
latently-infected host cell that is expanding [3,4], which would
explain the absence of this viral phenotype with the non-
oncogenic MD vaccines. Furthermore, several MDV genes, such as
Meq and vIL8, in the Rispens/CVI988 genome differ from those in
the oncogenic serotype 1 MDV and these variations likely con-
tribute to the attenuation of the vaccine-virus, which includes loss
of the cellular transformation capacity [38,42]. The absence of the
same transformation-associated genes in the SB-1 and HVT gen-
omes also explains their inability to induce lymphomas [43,44].
In this study, all vaccinated birds showed the viral chromo
some-associated/telomere-integrated phenotype, signifying that
MD vaccine-viruses are capable of integrating into host chromo-
somes. This finding was interesting considering that although the
viral telomeric repeats are intact within all vaccine genomes, the
Meq and vTR genes, which contribute to oncogenic MDV integra-
tion, are absent from SB-1 and HVT genomes [43–46], and in the
Rispens genome a functional copy of the Meq oncogene is lacking
[19,38,42]. The absence of the MDV telomere-integrated only phe-
notype in dividing splenic cell populations (largely T and B lym-
phocytes, monocytes, macrophages, etc.) of MD-vaccinated birds
was unsurprising given that the vaccines do not induce MD lym-
phomas. A DMeq MDV strain, which does not induce MD lym-
phomas [47], also did not demonstrate the telomere-integrated
only virus-host phenotype in host immune organs [5]. However,
it is interesting that the vaccines strains are all capable of telomeric
integration, even during early infection, but fail to transition into
the telomere-integrated only phase.
MD vaccines were found in numerous studies to replicate dur-
ing early infection (1–21 dpi) and at later timepoints post-
vaccination (up to 56 dpi) in various immune tissues (including
spleen) [10,35,48,49], reduce oncogenic MDV viral load in vivo
[49], and horizontally transmit through shed feather dander [48].
A distinct feature of all MD vaccine strains, demonstrated by our
data, was a prolonged and elevated incidence of the MDV
chromosome-associated phenotype in the spleen during early
infection (up to 21 dpi), which has been correlated with the timing
of lytic replication [4,5,11]. Unsurprisingly, variations in and/or the
absence of transformation-associated MDV genes in the MD vacci-
nes’ genomes [42–44] did not impact the cytolytic replication abil-
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Meq, have been implicated in serotype 1 MDV lymphoma develop-
ment, while their expression does not influence MDV replication
in vivo [25,47]. The prolonged cytolytic stage observed in the
MD-vaccinated birds may be, in part, explained by an inability of
the vaccine strains to efficiently transition into latency. A reduced
ability to establish latency has been suggested for the DMeq MDV
strain as well [47]. It may be that the prolonged replication of the
MD vaccines in host immune tissues leads to competitive exclusion
against virulent/oncogenic MDV, contributing to the protective
mechanism [50].
We have repeatedly employed molecular cytogenetics to study
MDV behavior, and observed early (1 dpi) viral replication [4,5].
Our current data indicate the presence of replicating oncogenic
MDV or vaccine-virus in host lymphoid tissue as early as 1 dpi,
contrasting with studies that first detected vaccine DNA at 3 dpi
in spleen [10]. The difference may be attributable in part to admin-
istration, i.e., subcutaneous versus intra-abdominal, and the differ-
ent resolving powers of single-cell cytogenetic versus polymerase
chain reaction (PCR)-based detection. There is undoubtedly varia-
tion among the MD vaccine-virus serotypes, in terms of timing,
duration, productivity and perhaps host immune tissue targeted
during viral replication, in addition to shared differences from
oncogenic MDV. However, it is clear from both cytogenetic and
PCR-based data that there is a productive vaccine-virus lytic repli-
cation stage in vaccinated, yet unchallenged, susceptible chickens.
A prolonged and increased cytolytic replication stage in lym-
phoid tissues has been observed for very virulent (vv) and very
virulent+ (vv+) MDV pathotypes as compared to virulent (v)
MDV by molecular methods, along with other key differences in
pathogenesis [51,52]. Investigations of Rispens, SB-1 and HVT indi-
cated that MD vaccine lytic replication, specifically viral load dur-
ing the timing of replication as detected by PCR-based techniques,
was reduced as compared to virulent/oncogenic MDV challenged
birds in the same immune tissues (splenic, thymic and bursal)
[53–55]. It has also been established that attenuation of serotype
1 MDV (i.e., Rispens vaccine development) is correlated with
decreased replication ability as well as the loss of oncogenic trans-
formation capacity [56]. This seems to suggest a positive correla-
tion between MDV strain virulency and productivity of the
cytolytic replication. Our molecular cytogenetic results indicate a
prolonged and augmented viral replication stage of the three MD
vaccine strains in splenic cell populations of highly susceptible
birds. There are key differences in the meaning of ‘viral load’ as
measured by PCR-based versus cytogenetic methods; namely, that
the PCR-based viral load indicates a quantity of viral genomes per
unit or volume of cells, whereas the cytogenetic load indicates a
quantity of cells with replicating viral genomes. Thus, the PCR-
based and cytogenetic data on MD vaccine versus oncogenic
MDV replication may demonstrate both a higher percent of host
splenic cells maintaining lytic MD vaccine replication (as detected
by cytogenetic methods) and a vaccine strain replication that is not
as productive in lytically-infected cells, resulting in a quantifiably
lower vaccine-virus load (as detected by PCR-based methods).
Additionally, molecular cytogenetic methods provide an enhanced
sensitivity for the detection of lytically replicating, yet low produc-
tion level, virus as compared to PCR quantification methods.
A remaining important question is whether the MD vaccines
innately transition to viral latency in host birds and how
vaccine serotype in addition to host MHC genotype, age and/or
immune status impact the vaccine strain behavior among the
immune organs (spleen, bursa of Fabricius and thymus). There have
been indications of latent HVT in the spleen at 70 dpi and in all lym-
phoid tissues (thymus, spleen and bursa) at 105 dpi, however this
finding did not exclude the possibility of vaccine-virus latency dur-
ing earlier timepoints after vaccination [57]. Furthermore, latent,and predominantly linear form, HVT and MDV genomes were
detected within a non-producer T-lymphoblastoid cell line devel-
oped from the spleen of an HVT-vaccinated chicken [58]. Their
results also indicated that latent viral genome replication, or trans-
mission to daughter cells, exploits host cell replication factors
rather than viral replication factors, which strongly suggested
integrated-virus genomic DNA in latently-infected cells. As men-
tioned above, the detection of the transitional virus-host phenotype
and the absence of the telomere-integrated only phenotype in the
spleen of MD-vaccinated birds suggest that the vaccine-viruses do
not efficiently transition to latency during early infection compared
to pathogenic MDV. An investigation of lymphoid tissue of vacci-
nated chickens from later timepoints (>21 dpi) may help elucidate
the temporal nature of MD vaccine strain latency.
Based on our cytogenetic results, it is evident that the MD vac-
cines maintain a prolonged lytic replication in host birds, and the
percentage of lytically-infected cells in MD-vaccinated birds is
higher than in birds challenged with oncogenic MDV. The MD vac-
cines also integrate at chicken host telomeres, although in a lower
percentage of cells as compared to oncogenic MDV. Interestingly,
the vaccines are similar to DMeq MDV [5] in behavior as both do
not lead to the integrated-only viral phenotype, which is a hall-
mark of oncogenic MDV latency and transformation, in host spleen
cells. The absence of a host cell population with integrated-MDV
only in vaccinated birds may be useful to elucidate the vaccines’
inability to establish latency during early infection and transform
host cells. Physical integration of the oncogenic MDV genome into
host telomeres along with cessation of viral replication appear to
be significant in MDV’s ability to induce disease symptoms and
oncogenic transformation in the host. This updated model of
oncogenic-MDV versus MD-vaccine behavior offers an improved
understanding of the mechanisms of vaccinal immunity and
should contribute to future MD vaccine research and development.
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